The role of platelets and platelet-derived microvesicles in diabetic nephropathy.

Completed

• Conditions: diabetic kidney injury; Diabetic nephropathy; 10012653; 10029149

• Registration Number: NL-OMON47280
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 144

Inclusion Criteria

Type 2 diabetes
Age between 18-70 year

Exclusion Criteria

Smoker
User of anti-platelet drugs
South-Asian or Sub-Sahara ethnicity

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main parameter of this study is the content of mRNA and miRNA in platelets<br /><br>and PMVs. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Plasma and urinary microvesicles and inflammatory markers (e.g. TNF-alpha,<br /><br>il-6, il-8, il-1*), renal injury markers (e.g. Cystatin-C, nGAL), as well as<br /><br>platelet activity markers (platelet factor 4 and serotonin) and agonist-induced<br /><br>platelet aggregation (platelet count-based test) are secondary study<br /><br>parameters. </p><br>